russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2015-5-123-126russjcardiol-331Research ArticleКЛИНИКА И ФАРМАКОТЕРАПИЯGUIDELINES FOR THE PRACTITIONERЦИТОПРОТЕКЦИЯ ТРИМЕТАЗИДИНОМ MB: СОВРЕМЕННЫЕ ДАННЫЕCYTOPROTECTION WITH TRIMETAZIDINE MB: RECENT DATAГордеевИ. Г.GordeevI. G.

д.м.н., профессор, заведующий кафедрой госпитальной терапии №1 л/ф

ЛучинкинаЕ. Е.LuchinkinaE. E.

к.м.н., доцент кафедры

ТаратухинЕ. О.TaratukhinE. O.

к.м.н., ассистент кафедры, доцент кафедры

cardio03@ya.ruГБОУ ВПО РНИМУ им. Н. И. Пирогова, Москва, РоссияРоссияSBEI HPE RNRMU n.a. N.I. Pirogov, Moscow, Russia.Russian Federation20152805201505123126Copyright © Гордеев И.Г., Лучинкина Е.Е., Таратухин Е.О., 20152015Гордеев И.Г., Лучинкина Е.Е., Таратухин Е.О.Gordeev I.G., Luchinkina E.E., Taratukhin E.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/331

Статья посвящена новым данным исследований цитопротектора триметази-дина MB. Приводится информация о недавно обнаруженных механизмах его эффекта, включая системное не связанное с миокардом действие. Приводятся результаты эпидемиологических исследований и мета-анализов, подтверждающие эффективность и безопасность препарата при ишемической болезни сердца и хронической сердечной недостаточности.

The article focuses on new data on trimetazidine MB cytoprotection studies. The data provided on novel mechanisms of its effect including systemic action not related to myocardium. The results of epidemiological studies and meta-analysis are provided that confirm safety and efficacy of the medication in ischemic heart disease and chronic heart failure.

хроническая сердечная недостаточностьстабильная ише-мическая болезнь сердцаметаболизмжирные кислотытриметазидин MBПредуктал MB.chronic heart failurestable ischemic heart diseasemetabolismfatty acidstrimetazidine MBPreductal MBReferencesESC Guidelines 2013 on the management of stable coronary artery disease. Eur Heart J, 2013;34:2949-3003.ESC Guidelines 2013 on the management of stable coronary artery disease. Eur Heart J, 2013;34:2949-3003.Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution). http://www. ema.europa.eu/ docs/en_GB/document_library/Referrals_document/Trimetazidine_31/WC500129195. pdf(9 March 2012).Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution). http://www. ema.europa.eu/ docs/en_GB/document_library/Referrals_document/Trimetazidine_31/WC500129195. pdf(9 March 2012).Liu YC, Li L, Su Q, et al. Trimetazidine pretreatment inhibits myocardial apoptosis and improves cardiac function in a Swine model of coronary microembolization. Cardiology, 2015; 130(2): 130-6.Liu YC, Li L, Su Q, et al. Trimetazidine pretreatment inhibits myocardial apoptosis and improves cardiac function in a Swine model of coronary microembolization. Cardiology, 2015; 130(2): 130-6.§enturk T, Cavun S, Avci B, et al. Effective inhibition of cardiomyocyte apoptosis through the combination of trimetazidine and N-acetylcysteine in a rat model of myocardial ischemia and reperfusion injury. Atherosclerosis, 2014; 237(2): 760-6.§enturk T, Cavun S, Avci B, et al. Effective inhibition of cardiomyocyte apoptosis through the combination of trimetazidine and N-acetylcysteine in a rat model of myocardial ischemia and reperfusion injury. Atherosclerosis, 2014; 237(2): 760-6.Peng S, Zhao M, Wan J, et al. The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials. Int J Cardiol, 2014; 177(3): 780-5.Peng S, Zhao M, Wan J, et al. The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials. Int J Cardiol, 2014; 177(3): 780-5.Chrusciel P, Rysz J, Banach M. Defining the Role of Trimetazidine in the Treatment of Cardiovascular Disorders: Some Insights on Its Role in Heart Failure and Peripheral Artery Disease. Drugs, 2014; doi: 10.1007/s40265-014-0233-5.Chrusciel P, Rysz J, Banach M. Defining the Role of Trimetazidine in the Treatment of Cardiovascular Disorders: Some Insights on Its Role in Heart Failure and Peripheral Artery Disease. Drugs, 2014; doi: 10.1007/s40265-014-0233-5.Tsioufis K, Andrikopoulos G, Manolis A. Trimetazidine and cardioprotection: facts and perspectives. Angiology, 2015; 66(3): 204-10.Tsioufis K, Andrikopoulos G, Manolis A. Trimetazidine and cardioprotection: facts and perspectives. Angiology, 2015; 66(3): 204-10.Winter JL, Castro PF, Quintana JC, et al. Effects of trimetazidine in nonischemic heart failure: a randomized study. J Card Fail, 2014; 20(3): 149-54.Winter JL, Castro PF, Quintana JC, et al. Effects of trimetazidine in nonischemic heart failure: a randomized study. J Card Fail, 2014; 20(3): 149-54.Vitale C, Spoletini I, Malorni W et al. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina — the VASCO-angina study. Int J Cardiol, 2013; 168(2): 1078-81.Vitale C, Spoletini I, Malorni W et al. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina — the VASCO-angina study. Int J Cardiol, 2013; 168(2): 1078-81.Zhang L, LuY, Jiang H, et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol, 2012; 59(10): 913-22.Zhang L, LuY, Jiang H, et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol, 2012; 59(10): 913-22.Zhou X, Chen J. Is treatment with trimetazidine beneficial in patients with chronic heart failure? PLoS One, 2014; 9(5): e94660.Zhou X, Chen J. Is treatment with trimetazidine beneficial in patients with chronic heart failure? PLoS One, 2014; 9(5): e94660.Dedkova EN, Seidlmayer LK, Blatter LA. Mitochondria-mediated cardioprotection by trimetazidine in rabbit heart failure. J Mol Cell Cardiol, 2013; 59: 41 -54.Dedkova EN, Seidlmayer LK, Blatter LA. Mitochondria-mediated cardioprotection by trimetazidine in rabbit heart failure. J Mol Cell Cardiol, 2013; 59: 41 -54.Gao D, Ning N, Niu X, et al. Trimetazidine: a meta-analysis of randomized controlled trials in heart failure. Heart, 2011; 97(4): 278-86.Gao D, Ning N, Niu X, et al. Trimetazidine: a meta-analysis of randomized controlled trials in heart failure. Heart, 2011; 97(4): 278-86.Fragasso G, Salerno A, Lattuada G, et al. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure. Heart, 2011; 97(18): 1495-500.Fragasso G, Salerno A, Lattuada G, et al. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure. Heart, 2011; 97(18): 1495-500.Liu F, Yin L, Zhang L, et al. Trimetazidine improves right ventricular function by increasing miR-21 expression. Int J Mol Med, 2012; 30(4): 849-55.Liu F, Yin L, Zhang L, et al. Trimetazidine improves right ventricular function by increasing miR-21 expression. Int J Mol Med, 2012; 30(4): 849-55.Fragasso G, Rosano G, Baek SH, et al. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study. Int J Cardiol, 2013; 163(3): 320-5.Fragasso G, Rosano G, Baek SH, et al. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study. Int J Cardiol, 2013; 163(3): 320-5.Grajek S, Michalak M. The effect of trimetazidine added to pharmacological treatment on all-cause mortality in patients with systolic heart failure. Cardiology, 2015; 131(1): 22-9.Grajek S, Michalak M. The effect of trimetazidine added to pharmacological treatment on all-cause mortality in patients with systolic heart failure. Cardiology, 2015; 131(1): 22-9.Loiacono F, Alberti L, Lauretta L, et al. Metabolic therapy for heart failure. Recenti Prog Med, 2014; 105(7-8): 288-94.Loiacono F, Alberti L, Lauretta L, et al. Metabolic therapy for heart failure. Recenti Prog Med, 2014; 105(7-8): 288-94.

The authors declare that there are no conflicts of interest present.